Kornimate/medical-research-clean huggingface dataset:
drug discovery for parkinson's with mutations in the gba gene

Conditions: Parkinson Disease; Gaucher Disease; Healthy; GBA Gene Mutation

Summary: the new york stem cell foundation (nyscf) research institute is performing this research to accelerate parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. through this research, researchers hope to identify future treatments or even cures for parkinson's disease.

researchers at the new york stem cell foundation (nyscf) research institute study diverse diseases, conditions, and traits by creating stem cells from biological samples. these "pluripotent" stem cells can become any cell in the human body, including cells that may be difficult, invasive, or impossible to obtain directly. additionally, researchers perform genetic testing to learn more about dna, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). a piece of dna that determines the specific role of a cell is called a "gene." if the instructions in a gene are abnormal, this can lead to disease. participation in the study involves: (1) completion of health questionnaires, (2) providing a skin and/or blood sample from which stem cells may be created, (3) collection of a saliva sample for genetic analysis, and (4) possible future follow-up to provide additional information or learn about other research studies. this study is not a clinical trial.

Eligibility criteria:
inclusion criteria: * age 18 years or older. * diagnosis of parkinson's disease, gaucher disease, or healthy control. * must provide written informed consent unless physical limitations preclude signing. exclusion criteria: * for skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection. * for blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection. * for all prospective sample collections: subjects who refuse to adhere to nyscf's and/or a collection site's safety protocols will be excluded. subjects with an aids diagnosis and cd4 count of less than 200 cells per microliter (mcl) of blood will be excluded due to increased risk of infection.

Keywords: parkinson disease gba gene mutation
improving maintenance following very low calorie diet: the sustain lost weight (slw) intervention

Conditions: Obesity

Summary: obtain a preliminary assessment of the feasibility and acceptability of delivering the sustained lost weight (slw) intervention in a real-world clinical setting for patients who have completed a 21-week very low calorie diet (vlcd). hypothesis: intervention will be feasible to implement as evidenced by the ability to recruit and retain participants and acceptable to participants as evidenced by self-report of satisfaction with the program and adoption of weight maintenance behaviors. secondary aim: obtain a preliminary assessment of the effectiveness of the sustained lost weight (slw) intervention for patients who have completed 21 weeks of a very low calorie diet (vlcd). hypothesis: greater than 75% of participants who receive this novel approach, where maintenance behaviors are individualized based on resting metabolic rate and a physical activity factor, will regain greater or equal to 10 kg. at week 52 follow-up.


Eligibility criteria:
inclusion criteria: * completed fast and transition period of the optifast® program * be able to participate fully in all aspects of the study * willing to refrain from participating in additional weight loss interventions for the duration of the study * willing to provide written informed consent. exclusion criteria: * myocardial infarction within 6 months * unstable angina * stroke * chronic steroid use * active peptic ulcer disease * advanced cirrhosis * active hepatitis * advanced renal disease * active thrombophlebitis * recent skeletal fractures * use of lithium * pancreatitis * pregnancy * type 1 diabetes mellitus * history of diabetic ketoacidosis * active bulimia nervosa * severe depression * psychosis * substance abuse
control systems engineering for weight loss maintenance

Conditions: Overweight and Obesity

Summary: this project capitalizes on principles of control systems engineering to build a dynamical model that predicts weight change during weight loss maintenance using behavioral, psychosocial, and environmental indicators evaluated in a system identification experiment. a 6-month behavioral obesity treatment will be administered to produce weight loss. participants losing at least 3% of initial body weight will be followed for an additional 12 months via daily smartphone surveys that incorporates passive sensing to objectively monitor key behaviors. survey data pertaining to behavioral, psychosocial, and environmental indicators will be used to develop a controller algorithm that can predict when an individual is entering a heightened period of risk for regain and why risk is elevated. interventions targeting key risk indicators will be randomly administered during the system id experiment. survey and passive sensing data documenting the effects of the interventions will likewise drive development of the controller algorithm, allowing it to determine which interventions are most likely to counter risk of regain.


Eligibility criteria:
inclusion criteria: * english language fluent and literate at the 6th grade level * body mass index (bmi) between 25 and 50 kg/m-squared * able to walk 2 city blocks without stopping * owns a smartphone exclusion criteria: * report of a heart condition, chest pain during periods of activity or rest, or loss of consciousness in the 12 months prior to enrolling. * currently participating in another weight loss program * currently taking weight loss medication * has lost ≥5% of body weight in the 6 months prior to enrolling * has been pregnant within the 6 months prior to enrolling * plans to become pregnant within 18 months of enrolling * any medical condition that would affect the safety of participating in unsupervised physical activity * any condition that would result in inability to follow the study protocol, including terminal illness and untreated major psychiatric illness
weight gain after smoking cessation and nafld

Conditions: Nonalcoholic Fatty Liver Disease; Type 2 Diabetes

Summary: nonalcoholic fatty liver disease (nafld) is rapidly becoming the most common chronic liver disease. considering that there are no approved pharmacological treatments, lifestyle modification is necessary and challenging to reduce the risk of type 2 diabetes mellitus (t2dm) in patients with nafld. cigarette smoking has a significant negative impact on public health, causing more than 480,000 deaths each year. smoking has been reported as a risk factor for nafld and might accelerate liver disease progression. therefore, it is recommended that patients with nafld quit smoking. however, smoking cessation could be complicated by weight gain. thus, it is important to assess the impact of weight change after smoking cessation on patients with nafld. proper management of post-cessation weight could maximize its health benefits. in this large-scale cohort study, the investigators aimed to assess the effects of smoking cessation and subsequent weight change on risks of incident t2dm in individuals with nafld.


Eligibility criteria:
inclusion criteria: (i) age\>=18 years. exclusion criteria: (i) with missing information on ultrasound, smoking status, and weight; (ii) with excess alcohol intake or history of chronic liver disease at baseline; (iii) female subjects.
fondaparinux in preventing blood clots in patients undergoing surgery for gynecologic cancer

Conditions: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Sarcoma; Thromboembolism; Vaginal Cancer; Vulvar Cancer

Summary: rationale: fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer. purpose: this phase ii trial is studying how well fondaparinux works in preventing blood clots in patients undergoing surgery for gynecologic cancer.

objectives: primary * evaluate the efficacy of prolonged (4 weeks) fondaparinux sodium administration in venous thromboembolism prophylaxis in patients undergoing gynecologic oncology surgery. secondary * evaluate the safety of this regimen in these patients (4 weeks). * determine the feasibility of this regimen in these patients (4 weeks). outline: this is an open-label study. beginning after surgery, patients receive fondaparinux sodium subcutaneously once daily on days 1-28 in the absence of disease progression or unacceptable toxicity. patients undergo duplex ultrasonography of the lower extremities between day 28-35.

Eligibility criteria:
inclusion criteria * scheduled to undergo major, open abdominal-pelvic surgery for known or presumed gynecologic malignancy * age 18 years or older at the time of signing the consent * gynecologic oncology group (gog) performance status of ≤ 2 * life expectancy of \> 3 months * patient's weight must be ≥ 50 kg * adequate organ function within 28 days of study entry defined as: * hemoglobin ≥ 9.0 g/dl * platelet ≥ 100,000 x 109/l * blood urea nitrogen (bun) ≤ 30 mg/dl * serum creatinine ≤ 1.5 mg/dl * not pregnant as determined by a negative urine or serum pregnancy test within 14 days of study enrollment * voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. exclusion criteria * current treatment with anticoagulants * thromboembolism within the previous 6 months * bleeding/blood disorders (e.g., thrombocytopenia), gastrointestinal bleeding (e.g., active ulcers), history of stroke within past 3 years, or severe and currently uncontrolled high blood pressure * bacterial endocarditis * known hypersensitivity to fondaparinux sodium

Keywords: thromboembolism cervical cancer endometrial cancer ovarian epithelial cancer ovarian germ cell tumor borderline ovarian surface epithelial-stromal tumor ovarian sarcoma ovarian stromal cancer uterine sarcoma vaginal cancer vulvar cancer fallopian tube cancer
a study to evaluate the safety, tolerability of incb160058 in participants with myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasms

Summary: this study is being conducted to assess the safety, tolerability, and pharmacokinetics of incb160058 in participants with myeloproliferative neoplasms.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * mf: intermediate-1 or higher risk pmf, post-pv mf, or post-et mf with evidence of minimum burden of disease based on splenomegaly and previously treated with at least 1 jak inhibitor for ≥ 12 weeks and resistant, refractory, intolerant to, or have lost response to jak inhibitor treatment. * pv: confirmed diagnosis of pv and previously treated with at least 1 prior standard cytoreductive therapy and are resistant, refractory, intolerant to, or have lost response to treatment. * et: confirmed diagnosis of high-risk et as defined in the protocol and previously treated with at least 1 prior standard cytoreductive therapy and are resistant, refractory, intolerant to, or have lost response to treatment. * life expectancy \> 6 months. * willingness to undergo a pretreatment and regular on-study bone marrow biopsies and aspirations (as appropriate to disease). * existing documentation of jak2v617f mutation from a qualified local laboratory. exclusion criteria: * presence of a hematological malignancy requiring treatment, other than pmf, post-pv mf, post-et mf, pv, or et. * prior history of major bleeding or thrombosis within the 3 months prior to study enrollment. * participants with abnormal hematologic, hepatic, or renal function based on laboratory evaluation. * has undergone prior allogenic or autologous stem-cell transplantation or allogenic stem-cell transplantation is planned * active invasive malignancy. * significant concurrent, uncontrolled medical condition. * acute or chronic hbv, active hcv or known hiv. * any prior mpn-directed therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment. * participants undergoing treatment with g-csf or gm-csf, romiplostim, or eltrombopag at any time within 4 weeks before the first dose of study treatment. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: myeloproliferative neoplasms incb160058 myelofibrosis
everolimus in breast cancer patients after pre-operative chemotherapy

Conditions: Breast Neoplasms

Summary: this is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy. patient will be randomized to undergo observation or to receive everolimus after completion of neoadjvuant treatment (anthracycline and/or taxane-based) and before surgery. the patients will be monitored for efficacy and safety.


Eligibility criteria:
inclusion criteria: * women aged ≥ 18 years; * histologically and/or cytologically confirmed invasive ductal or lobular breast cancer; * tumor of 3 cm or greater at time of diagnosis * measurable primary tumor after neoadjuvant treatment before randomization * no prior chemotherapy for breast cancer; * ecog performance status ≤1 or karnofsky performace status ≥ 70% * adequate liver/renal function * able to swallow whole tablets. * able to give written informed consent * able to follow prescription instructions reasonably well exclusion criteria: * male patient * prior history of other malignancy within 5 years of study entry, aside from contralateral breast carcinoma, appropriately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin * distant metastasis, including skin involvement beyond the breast area * other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study

Keywords: everolimus neoadjuvant m-tor inhibitor
a study of furmonertinib combined with radiotherapy for non-small cell lung cancer with oligoprogression

Conditions: Non-small Cell Lung Cancer; Oligoprogressive

Summary: this phase ii randomized study is to explore the efficacy and safety of furmonertinib combined with radiotherapy for non-small cell lung cancer with oligoprogression after first-line egfr-tki therapy.

this phase ii randomized study is to explore the efficacy and safety of furmonertinib combined with radiotherapy for non-small cell lung cancer with oligoprogression after first-line egfr-tki therapy. the first group will enroll nsclc patients with oligoprogression after using the first/second generation egfr-tki. the participants will receive furmonertinib 80mg and local radiotherapy as the following therapy. the other group will enroll nsclc patients with oligoprogression after using the third generation egfr-tki. the participants will receive furmonertinib 160mg and local radiotherapy as the following therapy.

Eligibility criteria:
inclusion criteria: * patients with locally advanced or metastatic nsclc who are diagnosed by histology or cytology and are not suitable for surgery or radiotherapy; * after receiving the first or second generation of egfr-tki treatment, the disease is oligoprogressive with 3-5 lesions (with imaging evidence), and the mutation is t790m+ (histological or hematological specimens, arms detection method); * after receiving osimertinib treatment in the past, the disease is oligoprogressive with 3-5 lesions (with imaging evidence), and the patient refused chemotherapy; * 18-80 years old; * ecog ps 0-2 scores; * organ and bone marrow functions were generally normal within 30 days before enrollment, including:ast, alt ≤ 2.5 × uln or ≤ 5 × uln (with liver metastasis); total bilirubin ≤ 1.5 × uln; neutrophils absolute value ≥ 1500 cells/mm3; creatinine clearance ≥45 ml/min; platelets ≥ 100,000 cells/mm3; hemoglobin ≥90g/l. * the baseline has measurable lesions defined by the recist 1.1 standard, and the progressive lesions should be treated with local radiotherapy; the definition of the lesion number includes: 1. when there are lesions on both adrenal glands, it is considered to be 2 metastases; 2. two consecutive vertebral lesions and a paravertebral lesion within 6 cm can be considered as one metastasis, and the non-contiguous vertebral lesions should be counted separately; 3. the adjacent lesions in the liver, lung, and mediastinum can be considered as a metastasis if one isocenter can be used for irradiation; 4. intracranial lesions are counted as 1 metastasis. * the patient signed an informed consent form. exclusion criteria: * severe or uncontrolled hypertension, diabetes, coronary artery stenosis, aortic dissection, aneurysm or acute bleeding disease; * any situation that increases the risk of qtc prolongation or arrhythmia; * left ventricular ejection fraction \<50%; * history of interstitial lung disease; * fev1%\<30% or dlco%\<40%; * insertion of egfr exon 20; * the researcher believes that the patient is inappropriate to participate in this trial.

Keywords: non-small cell lung cancer oligoprogressive furmonertinib combined with radiotherapy
imaging analysis following periodontal surgery

Conditions: Healing Wound; Periodontitis

Summary: this is a single centre, randomised, single-blind, parallel-group clinical trial that aims at evaluating the use of imaging (2d and 3d) in obtaining geometric and thermometric changes of postoperative healing patterns and comorbidities (facial swelling, oedema and inflammation) following two routine surgical procedures performed for the treatment of periodontal (gum) disease.

a surgery in a posterior sextant will be performed per patient. the surgical procedures being compared for their post-operative healing patterns are: 1. simplified papilla preservation flap (sppf) which is a conservative flap aiming at preserving the tissues between teeth. 2. resective periodontal flap with osseous recontouring (rpfo) which is a conventional surgery which involves hard and soft tissues resection. geometric (3d) surface imaging and thermal (2d) surface imaging will be used to assess the post-operative healing patterns and comorbidities (facial swelling, oedema and inflammation) following either of the surgical procedures.

Eligibility criteria:
inclusion criteria: 1. systemically healthy males and females ≥ 30 years of age. 2. participants must be willing to read, and sign a copy of the "informed consent form" (icf) form after reading the, "patient information leaflet" (pis), and after the nature of the study has been fully explained. 3. participants must present with clinical and radiographic evidence of periodontitis, with one interdental area of periodontal pocket depth (ppd) ≥6mm, bleeding on probing (bop), and clinical attachment level (cal) ≥6mm in any posterior sextant of their mouth (excluding third molars and the distal aspect of the second molars), or multiple sites (≥9) with ppd ≥5mm, bop, and cal ≥5mm. 4. participants must have completed a course of non-surgical periodontal therapy within 2 years prior to study commencement and have had maintenance including subgingival debridement within 6 months prior to assessment for eligibility. exclusion criteria: 1. medical history including diabetes or hepatic or renal disease, or other serious medical conditions or transmittable diseases e.g. cardiovascular disease or aids. 2. antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding the baseline exam. 3. history of alcohol or drug abuse. 4. self-reported pregnancy or lactation. 5. other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration that may interfere with the interpretation of the data.

Keywords: postoperative healing
mobile app intervention for sleep problems and alcohol use among veterans

Conditions: Alcohol Use Disorder; Insomnia

Summary: the goal of this clinical trial is to test the preliminary efficacy of a brief mobile app targeting insomnia symptoms among veterans. in this study, we will enhance the mobile app, insomnia coach, with content from brief alcohol interventions to help veterans reduce both insomnia symptoms and alcohol use behaviors. we will compare those veterans who are randomly assigned to receive this brief mobile app intervention to those who receive a control condition. this will help us determine if veterans randomly assigned to receive the intervention experience greater improvement on outcomes compared to those who do not receive the intervention. the study involves a beta-test phase of the app to ensure feasibility and acceptability by veterans, followed by a randomized controlled trial with 130 veterans who meet criteria for insomnia and alcohol use disorder.


Eligibility criteria:
inclusion criteria: * u.s. veteran aged 18 or older separated or discharged from service in the air force, army, marine corps, navy, or coast guard * not currently affiliated with active duty service or on active reserves or guard service * served since september 11, 2001 * no past 6-month treatment for alcohol or drug use or insomnia * alcohol use disorder identification test (audit) score of 8 or higher * insomnia severity index (isi) score of 10 or higher exclusion criteria: * positive screening for other substance use disorders (not including cannabis use disorder)